The results also suggest similarities between urothelial and esophagogastric cancers, a cancer type in which ERBB2 heterogeneity and selection for ERBB2 wildtype subclones has been shown to be a common mechanisms of resistance to HER2-directed therapies44–47. The gene discussed is ERBB2; the disease is cancer.